Efficacy of Moclobemide in Burning Mouth Syndrome: A Nonrandomized, Open-Label Study

Aims: To compare burning mouth syndrome (BMS) patients with age- and gender-matched controls for psychologic conditions, to analyze the effect of menstrual state on the intensity of burning, and to assess the efficacy of an antidepressant medication on the burning pain and psychologic status. Methods: Ninety-four patients with BMS and 94 matched control subjects participated in the study. Anxiety and depression were analyzed by means of the Spielberger State-Trait Anxiety Inventory and Zung Self-Rating Depression Scale, and the severity of the burning sensation was measured by means of a visual analog scale (VAS). In female BMS patients and controls, the menstrual state was noted (menstruating, menopausal, or postmenopausal). BMS patients were treated with the antidepressant moclobemide (150 mg 2 times daily) for 3 months. Thereafter, anxiety, depression, and burning pain intensity were reassessed. Patient-perceived satisfactory improvement for burning sensation was assessed using a 5-point categorical rating of change scale. Results: BMS patients had significantly higher anxiety and depression scores than controls (P < .05). After treatment, anxiety and depression scores as well as the VAS values for burning pain decreased significantly (P< .001). Thirty-seven patients reported good to very good improvement, and 44 reported satisfactory improvement. No adverse reactions were reported. Conclusions: The study confirmed earlier reports that BMS patients have higher anxiety and depression levels than controls. An antidepressant medication may be effective in alleviating the burning pain, at least in the short term.

anxiety; burning mouth syndrome; depression; moclobemide; pain measurement; treatment

1. Suarez P, Clark GT. Burning mouth syndrome: An update on diagnosis and treatment methods. J Calif Dent Assoc 2006;34:611–622.

2. Al Quran FA. Psychological profile in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:339–344.

3. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002;65:615–620.

4. Zakrzewska JM. The burning mouth syndrome remains an enigma. Pain 1995;62:253–257.

5. Lamey PJ, Freeman R, Eddie SA, Pankhurst C, Rees T. Vulnerability and presenting symptoms in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:48–54.

6. Pekiner FN, Ozbayrak S, Canakcı E. Burning mouth syndrome in patients wearing prosthesis: Evaluation of type I and type II. The Pain Clinic 2005;17:269–273.

7. Zegarelli DJ. Burning mouth: An analysis of 57 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1984;58:34–38.

8. Lamb AB, Lamey PJ, Reeve PE. Burning mouth syndrome: Psychological aspects. Br Dent J 1988;165:256–260.

9. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: Overview and patient management. Crit Rev Oral Biol Med 2003;14:275–291.

10. Browning S, Hislop S, Scully C, Shirlaw P. The association between burning mouth syndrome and psychosocial disorders. Oral Surg Oral Med Oral Pathol 1987;64:171–174.

11. Hampf G, Vikkula J, Ylipaavalniemi P, Aalberg V. Psychiatric disorders in orofacial dysaesthesia. Int J Maxillofac Surg 1987;16:402–407.

12. van der Ploeg HM, van der Wal N, Eijkman MA, van der Waal I. Psychological aspects of patients with burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987;63:664–668.

13. Grushka M, Sessle BJ, Miller R. Pain and personality profiles in burning mouth syndrome. Pain 1987;28:155–167.

14. Bergdahl J, Anneroth G, Perris H. Personality characteristics of patients with resistant burning mouth syndrome. Acta Odontol Scand 1995;53:7–11.

15. Jerlang BB. Burning mouth syndrome (BMS) and the concept of alexithymia—A preliminary study. J Oral Pathol Med 1997;26:249–253.

16. Rojo L, Silvestre FJ, Bagan JV, De Vicente T. Psychiatric morbidity in burning mouth syndrome. Psychiatric interview versus depression and anxiety scales. Oral Surg Oral Med Oral Pathol 1993;75:308–311.

17. Forabosco A , Criscuolo M, Coukos G, et al. Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol 1992;73:570–574.

18. Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: A randomized controlled trial. J Orofac Pain 2004;18:131–137.

19. Grushka M, Sessle BJ, Howley TP. Psychophysical evidence of taste dysfunction in burning mouth syndrome. Chem Senses 1986;11:485-498.

20. Grushka M, Sessle BJ, Howley TP. Psychophysical assessment of tactile, pain, and thermal sensory functions in burning mouth syndrome. Pain 1987;28:169–184.

21. Svensson P, Kaaber S. General health factors and denture function in patients with burning mouth syndrome and matchedcontrol subjects. J Oral Rehabil 1995;22: 887–895.

22. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: A single-blind study. J Clin Psychiatry 2002;63:38–43.

23. Zilli C, Brooke RI, Lau CL, Merskey H. Screening for psychiatric illness in patients with oral dysaesthesia by means of the General Health Questionnaire-twenty-eight item version (GHQ-28) and Irritability, Depression and Anxiety Scale (IDA). Oral Surg Oral Med Oral Pathol 1989;67:384–389.

24. Lamey PJ, Lamb AB, Hughes A, Milligan KA, Forsyth A. Type 3 burning mouth syndrome: Psychological and allergic aspects. J Oral Pathol Med 1994;23:216–219.

25. Eli I, Kleinhauz M, Baht R, Littner M. Antecedents of burning mouth syndrome (glossodynia)—Recent life events vs. psychopathologic aspects. J Dent Res 1994;73:567–572.

26. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J 1988;296:1243–1246.

27. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.

28. Bonnet U. Moclobemide: Therapeutic use and clinical studies. CNS Drug Rev 2003;9:97–140.

29. Kendrick DB, Strout TD. The minimum clinically significant difference in patient-assigned numeric scores for pain. Am J Emerg Med 2005;23:828–832.

30. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain 2003;105:151–157.

31. ten Klooster PM, Drossaers-Bakker KW, Taal E, van de Laar MA. Patient-perceived satisfactory improvement (PPSI): Interpreting meaningful change in pain from the patient’s perspective. Pain 2006;121:151–157.

32. Lamey PJ, Lamb AB. The usefulness of the HAD scale in assessing anxiety and depression in patients with burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1989;67:390–392.

33. Pedersen AML, Smidt D, Nauntofte B, Christiani CJ, Jerlang BB. Burning mouth syndrome: Etiopathogenic mechanisms, symptomatology, diagnosis and therapeutic approaches. Oral Biosci Med 2004;1:3–19.

34. Wardrop RW, Hailes J, Burger H, Reade PC. Oral discomfort at menopause. Oral Surg Oral Med Oral Pathol 1989;67:535–540.

35. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987;63:30–36.

36. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome: A systematic review. J Orofac Pain 2003;17:293–300.

37. Pinto A, Sollecito TP, DeRossi SS. Burning mouth syndrome. A retrospective analysis of clinical characteristics and treatment outcomes. N Y State Dent J 2003;69:18–24.

38. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: Presentation and treatment. Br Med J 1984;288: 436–438.

39. Woda A, Navez ML, Picard P, Gremeau C, Pichard-Leandri

E. A possible therapeutic solution for stomatodynia (burning mouth syndrome). J Orofac Pain 1998;12:272–278.

40. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: Short-term results of a pilot study. J Oral Pathol Med 2004;33:111–114.

41. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226–247.

42. Dingemanse J, Kneer J, Fotteler B, Groen H, Peeters P, Jonkman JH. Switch in treatment from tricyclic antidepressants to moclobemide: A new generation monoamine oxidase inhibitor. J Clin Psychopharmacol 1995;15: 41–48.

43. Silverstone T. Moclobemide—Placebo controlled trials. Int Clin Psychopharmacol 1993;7:133–136.

44. Feine JS, Lavigne GJ, Dao TT, Morin C, Lund JP. Memories of chronic pain and perceptions of relief. Pain 1998;77:137–141.